Dr. Eddie Garon considers the data on immunotherapies for first line treatment of advanced NSCLC and whether we are likely to use these agents instead of or in combination with standard chemotherapy soon.
UCLA Med Center's Dr. Eddie Garon discusses the open question of the optimal duration of ongoing treatment with immunotherapy for lung cancer.
Dr. Jack West, Brendan Bietry, and Janet Freeman-Daily take questions from the audience about financial assistance, legal protections, and patient support.
Janet Freeman-Daily, a ROS1 lung cancer patient since 2011, talks about the importance of patients' involvement in their own health care and the support that exists online to help patients navigate the system.
Drs. Jack West and Greg Riely field questions about which treatments should EGFR lung cancer patients consider when their cancers progress.
Drs. Leora Horn, Ben Solomon, & Jack West consider the factors that might lead us to favor testing for PD-L1 at initial workup of a patient with advanced NSCLC or after progression.
Drs. Leora Horn, Ben Solomon, & Jack West consider the factors that might lead us to favor testing for PD-L1 at initial workup of a patient with advanced NSCLC or after progression.
Immune checkpoint inhibitors are now becoming approved and commercially available for patients with previously treated advanced NSCLC. Dr. Eddie Garon, medical oncologist at UCLA, summarizes key data and explains their current role in treatment.
Immune checkpoint inhibitors are now becoming approved and commercially available for patients with previously treated advanced NSCLC. Dr. Eddie Garon, medical oncologist at UCLA, summarizes key data and explains their current role in treatment.
Drs. Ben Solomon, Leora Horn, & Jack West consider how valuable testing for PD-L1 expression is in clinical practice and whether it should be integrated in clinical decision making around immunotherapies.
II've been battling sever left shoulder and arm pain for nearly 3 years now. I was sent to an orthopedic doc who found my left shoulder all messed up...
History- Diagnosis in February, metastasis to thyroid, lymph nodes, chest wall. Malignant pleural effusion-had pleurex cathether which was recently...
Hey, everyone! I'm writing as my mom (60, lung and some bone mets from breast cancer, now over 2nd line chemo with Taxol after Faslodex failed) is...
History- Diagnosis in February, metastasis to thyroid, lymph nodes, chest wall. Malignant pleural effusion-had pleurex cathether which was recently...
Hello, After inital dx with large tumor in lung and mediastinum NED. Adeno/Kras. After 1 yr brainmet. Since then 5 other brainmets in period of 12...
Dr. David Spigel, Sarah Cannon Cancer Center, describes current research in immunotherapy as treatment for squamous lung cancer.
[powerpress]
Dr. David Spigel, Sarah Cannon Cancer Center, outlines treatment options for squamous lung cancer.
[powerpress]
Squamous Lung Cancer, Part 3: Treatment Audio Podcast
Why do we care about lymph nodes when staging lung cancer?
Dr. David Spigel, Sarah Cannon Cancer Center, discusses the importance of genomic testing in squamous lung cancer.
[powerpress]
One of the challenges of the increased frequency of chest CT scans being done for screening of people at higher risk of lung cancer, or done more commonly for chest symptoms, is that lung nodules are very commonly found, but most the time they aren't cancer. Most studies show that >90% of lung nodules are benign, but the majority lead to additional work-up, and in nearly 100% of cases, they cause anxiety for the patient. What if a blood test could help clarify the probability that someone doesn't have a lung cancer?
Over the past 10 years we've come to recognize that what is lumped together as "lung cancer" is actually a wide range of different cancers that behave in their own patterns and respond very differently to different treatments. Some of our greatest advances in the field have come from the recognition of the complex patterns, but it has also become more challenging to do trials for small groups that represent just 1 or 2% of the larger whole.
Back in 2009, GRACE did a live educational meeting in Seattle, geared toward patients and caregivers, that coincided with a lung cancer conference offered to physicians. It included brief (~15 minute) talks by about 10 different specialists, ranging in topics from initial workup to what surgery entails, new options in radiation therapy, optimal management of patients with early stage and locally advanced lung cancer, as well as discussion of emerging new treatments for advanced lung cancer.
Every October, the world is awash in bright pink and around the clock promotions to raise money and awareness for breast cancer, a terrible disease for which the amount of funding and awareness is the source of envy for every other cancer.
For early stage NSCLC, the historic standard of care is a lobectomy. But the reality is that with the median age of patients with new lung cancer a little over 70 and many patients quite sick from their lung cancer, COPD, and/or other medical problems, not every patient is a great candidate for surgery.
We're thrilled to be working again with LUNGevity Foundation to bring you another webinar just in time for November as lung cancer awareness month. On Tuesday, November 12th, at 2 PM Eastern/11 AM Pacific, Dr. David Spigel from Sarah Cannon Cancer Center in Nashville, TN will lead us in a very timely discussion of current and future management issues in squamous cell non-small cell lung cancer (NSCLC), a subtype that comprises 20-25% of NSCLC but has historically been more known for treatments you don't offer than for specific treatment options that are especially appealing for it.
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.